2020/2786(DEA)
Inclusion of the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in the definition of 'drug' (amend. the Annex to Council Framework Decision 2004/757/JHA)
Basic information
2020/2786(DEA)
DEA - Delegated acts procedure
Supplementing 2013/0304(COD)
Subject
4.20.03 Drug addiction, alcoholism, smoking
7.30.30.04 Action to combat drugs and drug-trafficking
Status
Procedure completed - delegated act enters into force
Key players
-
European Parliament
Committee responsible Rapporteur Appointed
Key events
| Date | Event | Reference | Summary |
|---|---|---|---|
| 02/09/2020 | Non-legislative basic document published | C(2020)05897 | |
| 09/09/2020 | Initial period for examining delegated act 2 month(s) | ||
| 16/09/2020 | Committee referral announced in Parliament | ||
| 17/11/2020 | Delegated act not objected by Parliament |
Technical information
| Procedure reference | 2020/2786(DEA) |
|---|---|
| Procedure type | DEA - Delegated acts procedure |
| Procedure subtype | Examination of delegated act |
| Amendments and repeals | Supplementing 2013/0304(COD) |
| Stage reached in procedure | Procedure completed - delegated act enters into force |
| Committee dossier |
LIBE/9/04106
|
Documentation gateway
-
Document type Reference Date Summary Non-legislative basic document C(2020)05897 02/09/2020